Table 1.
Overview of miRNA candidates misregulated in EBV positive relative to EBV negative counterpart DLBCL library and their known relation to cancer
| microRNA species | Fold change | Known relation to cancer | Refererence | Name of journal | Issue |
|---|---|---|---|---|---|
| hsa-miR-223 | 4.48 up | miR-223, miR-26b, miR-23b, miR-23a are significantly upregulated in kidney and bladder cancers | Gottardo et al. 2007 | Urologic Oncology | 25(5): 387–392 |
| E2F1 and microRNA-223 comprise an autoregulatory negative feedback loop in AML | Pulikkan et al. 2010 | Blood | 4;115(9): 1768–1778 | ||
| hsa-miR-199a/b-3p | 3.81up | Expression is correlated with worse overall and event free survival in AML | Garzon et al. 2008 | Blood | 111(6): 3183–3189 |
| hsa-miR-424 | 3.78 up | PU.1 activates the transcription of miR-424 and is involved in stimulating monocyte differentiation | Rosa et al. 2007 | Proceedings of the National Academy of Sciences of the United States of America | 104(50): 19849–19854 |
| Acts pro-differentiative and modulates cell cycle regulators in AML | Forrest et al. 2010 | Leukemia | 24(2): 460–466 | ||
| hsa-miR-27b | 3.56 up | Expression of miR-27b contributes to in vitro angiogenesis | Kuehbacher 2008 | Trends in Pharmacological Science | 29(1): 12–15 |
| hsa-miR-378 | 3.43 up | MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression | Lee et al., 2007 | Proceedings of the National Academy of Sciences of the United States of America | 104(51): 20350–20355 |
| hsa-miR-26b | 2.35 up | Reduced expression in hepatocellular carcinoma | Ji et al. 2009 | New England Journal of Medicine | 361(15): 1437–1447 |
| hsa-miR-23a | 2.27 up | Upregulated in EBV+ lymphoblastoid cell lines | Mrazek et al. 2008 | Nucleic Acids Research | 35(10): e73 |
| hsa-miR-199a-5p | 2.17 up | ||||
| hsa-miR-23b | 2.11 up | MicroRNA-23b mediates urokinase and c-met downmodulation and a decreased migration of human hepatocellular carcinoma cells | Salvi et al. 2009 | FEBS Journal | 276(11): 2966–2982 |
| Suppressed by c-MYC | Gao et al. 2009 | Nature | 458(72,3,9): 762–765 | ||
| hsa-miR-20b | 7.91 down | Oncogenic potential of the miR-106-363 cluster and has implication in human T-cell leukemia | Landais et al. 2007 | Cancer Research | 67(12): 5699–5707 |
| hsa-miR-155 | 4.41 down | Oncogene, upregulated in EBV+ Lymphoblastoid cell lines | Mrazek et al. 2007 | Nucleic Acids Research | 35(10): e73 |
| Costinean et al. 2006 | Proceedings of the National Academy of Sciences of the United States of America | 103(18): 7024–7029 | |||
| hsa-miR-221 | 3.99 down | miR-221 were more highly expressed in ABC-type than GCB-type cell lines; over-expressed in de novo DLBCLtransformed DLBCL | Lawrie et al. 2007 | International Journal of Cancer | 121(5): 1156–1161 |
| hsa-miR-151-3p | 3.26 down | ||||
| hsa-miR-222 | 2.49 down | See miR-221 | |||
| hsa-miR-29b/29c | 2.37 down | mir-29 regulates Mcl-1 (anti-apoptotic BCL-2 member) protein expression and apoptosis | Mott et al. 2007 | Oncogene | 26(42): 6133–6140 |